Horizon Discovery

Horizon Discovery

Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation.

Telephone: +44 (0)1223 976 000
Address: Building 8100, Cambridge Research Park, Waterbeach
Postcode: CB25 9TL
Country: United Kingdom
Website: http://www.horizondiscovery.com
Membership type:Founder Member

Horizon Discovery Group plc, a UK headquartered global life science company, is a world leader in gene editing and gene modulation.

Through the application of these technologies the Company enables researchers to alter almost any gene or modulate its function in human or mammalian cells to generate models that mimic the genetic abnormalities found in diseases such as cancer. Horizon offers a catalogue of over 1,000,000 cell and reagent products, which along with related research services, support a greater understanding of the function of genes across all species and the genetic drivers of disease, and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, and are used in the Company’s own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”. www.horizondiscovery.com

Terry Pizzie

Horizon Discovery appoints Terry Pizzie as Chief Executive Officer

Horizon Discovery Group plc), a global leader in gene editing and gene modulation technologies, is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect.

8 May 2018Read in full

Horizon and Pirbright Institute support research into improvement of vaccine yields

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that it has extended its biomanufacturing capabilities through an agreement with The Pirbright Institute to jointly work on a research programme aimed at deploying cell engineering to increase the yields of livestock vaccines.

12 April 2018Read in full

Horizon Discovery’s Bioproduction cell line used as part of a successful drug (IND) filing

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, today announces that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND) filing with the United States Food and Drug Administration (USFDA).

22 March 2018Read in full

Horizon Discovery announces leadership changes

Horizon Discovery Group plc (LSE: HZD), a global leader in gene editing and gene modulation technologies, today announces that Dr Darrin M. Disley has decided to step down as Chief Executive Officer in order to pursue other business interests.

20 February 2018Read in full

Activation of IL1R2 with Edit-R CRISPRa

Horizon Discovery’s Dharmacon introduces Edit-R CRISPRa reagent platform

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announced the launch of its reagent platform for CRISPR activation (CRISPRa) from its recently acquired Dharmacon™ business. This is the latest addition to the company’s market-leading Edit-R™ portfolio for CRISPR-Cas9 genome engineering.

14 November 2017Read in full

Horizon Discovery partners with The Michael J. Fox Foundation for Parkinson’s research

Horizon Discovery partners with The Michael J. Fox Foundation for Parkinson’s research

Horizon Discovery, a global leader in gene editing and gene modulation technologies, in partnership with The Michael J. Fox Foundation for Parkinson's Research (MJFF), today introduced two new gene knock-out and knock-in rat models for investigating the role of alpha-synuclein in brain function and Parkinson’s disease (PD) pathogenesis.

31 October 2017Read in full

Horizon Discovery Group delivers consistent strong growth

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, is positioned for additional scale following its transformational acquisition of GE Healthcare Dharmacon, Inc. The company has announced its interim results for the six months ended 30 June 2017.

27 September 2017Read in full

Horizon Discovery introduces OncoSpan, the world’s largest reference standard for oncology

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces the launch of OncoSpan, a novel cell line-derived multiplex DNA Reference Standard to support the validation of Next Generation Sequencing (NGS) assays.

25 September 2017Read in full

Horizon Discovery launches genome-wide CRISPRi and CRISPRa screening services

Horizon Discovery, a global leader in gene editing and gene modulation technologies, today announces that it has expanded its functional genomic screening portfolio to include first-to-market CRISPRi (interference) and CRISPRa (activation) screening services.

18 September 2017Read in full

Horizon Discovery releases CHO genome sequence to drive innovation in bioproduction

Horizon Discovery, a global leader in the application of gene editing technologies, today announced it has released a complete, high-quality, well annotated sequence of its GS Knockout CHO-K1 bioproduction cell line. The sequence will be made available publicly via the Ensembl website at EMBL-EBI, to serve the community as a resource to drive research and innovation in bioproduction at Horizon and across the industry.

1 August 2017Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. ...
  12. 21